Patient reported outcomes for the CANDOR trial for multiple myeloma

Bookmark and Share
Published: 13 Jun 2020
Views: 513
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Prof Katja Weisel speaks to ecancer online at the EHA virtual conference 2020 about the CANDOR trial patient reported outcomes.

She explains how the patients reported their outcomes through a life-quality evaluation questionnaire, and explains why this feedback is so important.

Prof Weisel emphasises why this especially important in diseases like multiple myeloma because patients can live a long time with treatment, and constant feedback is important for a better quality of life.


ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.